AxoGen (NASDAQ:AXGN) Price Target Raised to $55.00

AxoGen (NASDAQ:AXGN) had its price objective increased by investment analysts at Citizens Jmp from $50.00 to $55.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has a “market outperform” rating on the medical equipment provider’s stock. Citizens Jmp’s target price points to a potential upside of 27.52% from the company’s previous close.

Several other analysts have also commented on AXGN. Wells Fargo & Company lifted their price target on shares of AxoGen from $40.00 to $48.00 and gave the company an “overweight” rating in a research report on Wednesday, April 29th. Truist Financial set a $55.00 price objective on AxoGen in a research report on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of AxoGen in a research report on Friday, May 29th. Wall Street Zen raised AxoGen from a “hold” rating to a “buy” rating in a research note on Sunday. Finally, Canaccord Genuity Group increased their price target on AxoGen from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $50.44.

AxoGen Trading Up 4.3%

AxoGen stock traded up $1.76 during midday trading on Thursday, hitting $43.13. 254,281 shares of the stock were exchanged, compared to its average volume of 1,116,078. The company has a current ratio of 7.10, a quick ratio of 5.33 and a debt-to-equity ratio of 0.08. The stock’s 50-day simple moving average is $42.10 and its 200 day simple moving average is $37.28. AxoGen has a fifty-two week low of $12.39 and a fifty-two week high of $46.95. The stock has a market capitalization of $2.29 billion, a price-to-earnings ratio of -67.97 and a beta of 1.09.

AxoGen (NASDAQ:AXGN) last posted its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.12 earnings per share for the quarter, meeting the consensus estimate of $0.12. AxoGen had a negative net margin of 13.21% and a negative return on equity of 9.63%. The company had revenue of $69.73 million for the quarter, compared to analyst estimates of $67.10 million. On average, equities analysts anticipate that AxoGen will post -0.37 EPS for the current year.

Insider Activity at AxoGen

In related news, Director Amy Mcbride Wendell sold 1,647 shares of the business’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $42.60, for a total transaction of $70,162.20. Following the completion of the transaction, the director directly owned 93,826 shares of the company’s stock, valued at $3,996,987.60. The trade was a 1.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Kathy Johnson Weiler sold 16,344 shares of the stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $44.09, for a total value of $720,606.96. Following the completion of the sale, the director directly owned 16,344 shares in the company, valued at $720,606.96. This represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 29,041 shares of company stock worth $1,268,792. Company insiders own 2.44% of the company’s stock.

Institutional Investors Weigh In On AxoGen

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Balyasny Asset Management L.P. grew its stake in shares of AxoGen by 183.9% during the second quarter. Balyasny Asset Management L.P. now owns 1,931,158 shares of the medical equipment provider’s stock worth $20,953,000 after purchasing an additional 1,250,968 shares in the last quarter. Wasatch Advisors LP raised its stake in AxoGen by 101.1% in the first quarter. Wasatch Advisors LP now owns 1,857,350 shares of the medical equipment provider’s stock valued at $61,534,000 after buying an additional 933,778 shares in the last quarter. Millennium Management LLC lifted its holdings in AxoGen by 2,255.8% during the 4th quarter. Millennium Management LLC now owns 971,358 shares of the medical equipment provider’s stock worth $31,793,000 after buying an additional 930,126 shares during the last quarter. Next Century Growth Investors LLC purchased a new stake in AxoGen during the 4th quarter worth about $26,180,000. Finally, Perceptive Advisors LLC acquired a new position in shares of AxoGen during the 4th quarter worth about $25,665,000. 80.29% of the stock is currently owned by institutional investors and hedge funds.

Key AxoGen News

Here are the key news stories impacting AxoGen this week:

• Positive Sentiment: AxoGen reported second-quarter revenue of $69.73 million, above the $67.10 million analyst estimate. Earnings were $0.12 per share; this matched the broader consensus cited by MarketBeat and exceeded the $0.09 Zacks consensus estimate. AxoGen Second Quarter 2026 Financial Results
• Positive Sentiment: The earnings coverage highlighted continued strong revenue growth, supporting the investment case for AxoGen’s peripheral nerve repair products and helping drive the favorable stock reaction. AxoGen Q2 2026 Earnings Call Highlights
• Neutral Sentiment: Management updated its fiscal 2026 earnings guidance, but the available report does not provide the revised figures, limiting the ability to assess whether the outlook improved or weakened. AxoGen Q2 2026 Earnings Call Transcript
• Negative Sentiment: Despite the revenue and adjusted-EPS performance, AxoGen continues to face margin pressure. The company reported a negative net margin of 13.21% and negative return on equity, while analysts expect a full-year loss of approximately $0.37 per share. AxoGen Q2 2026 Earnings

About AxoGen

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.